使用FAERS药监数据评估的与triptorelin相关的不良事件
Wei Jia1,2, Tiezhou Wang3
1Department of Pharmacy, Tonglu branch Hospital, Hangzhou First People's Hospital, No.899 Meilin Road, Tonglu, Hangzhou, 330000, Zhejiang Province, China. weij8341@163.com.
Scientific reports
|September 1, 2025
概括
这项研究分析了GnRH激动剂三素的现实不良反应, 揭示了一些意想不到的安全信号, 建议对这种前列腺癌和子宫内膜异位症药物进行持续监测.
科学领域:
- 药物监督和药物安全
- 癌症和内分泌学
背景情况:
- 特里普托林是一种性腺激素释放激素 (GnRH) 激动剂,是美国食品和药物管理局批准的治疗晚期前列腺癌,子宫内膜异位症和中部早期青春期的药物.
- 在临床试验之外,对现实世界不良事件 (AE) 进行分析对于了解药物安全至关重要.
研究的目的:
- 描述三素的实际不良事件 (AE) 概况.
- 使用大型不良事件数据库识别潜在的统计安全信号.
主要方法:
- 使用FDA不良事件报告系统 (FAERS) 的 2004 Q1 - 2024 Q3 的数据进行了回顾性药监测研究.
- 使用四种算法 (ROR,PRR,BCPNN,MGPS) 来检测AE信号的不成比例分析.
- 在1850万份FAERS报告中分析了4018份三素嫌疑报告.
主要成果:
- 确定了102个具有统计意义的优先条款.
- 意想不到的信号包括挑行为和阿尔茨海默氏症痴呆症,符合EMA进一步调查的标准.
- 艾滋病的发病模式是双模的,性别之间有不同的特征.
结论:
- FAERS数据显示出三素的预期和意外安全信号.
- 挑战性行为和阿尔茨海默氏症痴呆症代表了需要临床验证的重大潜在安全问题.
- 建议持续进行药物监测,以监测三瑞林的安全性.
相关概念视频
Pharmacovigilance
983
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
983
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
395
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
395
Clinical Trials
7.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
7.8K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
593
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
593
Drugs for Treatment of Diarrhea-Predominant IBS
292
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
292

![Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F63025.jpg&w=3840&q=50)
